Page 75 - 2021_09-Haematologica-web

Zanubrutinib in treatment naïve del(17p) CLL/SLL
al. Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients. Intern Med J. 2016;46(12):1414-1421.
31. Royle JA, Baade PD, Joske D, et al. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer. 2011;105(7):1076-1081.
32.Fischer K, Bahlo J, Fink AM, et al. Long- term remissions after FCR chemoim- munotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208-215.
33.Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425-2437.
34. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunother- apy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432-443.
35. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoim- munotherapy in older patients with untreated CLL. N Engl J Med. 2018; 379:2517-2528.
36.Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlo- rambucil plus obinutuzumab in first-line
treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43-56.
37. Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16 (2):169-176.
38.Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibruti- nib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131(21):2357-2366.
39.Oscier DG, Wade R, Orchard J, et al. Prognostic factors in the UK LRF CLL4 trial. Blood. 2006;108(11):299.
40. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophos- phamide for patients with chronic lympho- cytic leukaemia (the LRF CLL4 Trial): a ran- domised controlled trial. Lancet. 2007; 370(9583):230-239.
41. Strati P, Keating MJ, O'Brien SM, et al. Outcomes of first-line treatment for chron- ic lymphocytic leukemia with 17p deletion. Haematologica. 2014;99(8):1350-1355.
42. Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to
Richter syndrome. J Exp Med. 2013;
210(11):2273-2288.
43. Tam CS, Opat S, Zhu J, et al. Pooled analy-
sis of safety data from monotherapy stud- ies of the Bruton tyrosine kinase (BTK) inhibitor, zanubrutinib (BGB-3111) in B-cell malignancies. Presented at: 24th European Hematology Association Congress; June 13-16, 2019; Amsterdam, the Netherlands.
44.Hillmen P, Brown JR, Eichhorst BF, et al. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol. 2020;16(10):517-523.
45. Tam CS, LeBlond V, Novotny W, et al. A head-to-head phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. Future Oncol. 2018;14(22):2229-2237.
46.Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treat- ment of CLL. N Engl J Med. 2019; 380(22):2095-2103.
47. Lampson BL, Tyekucheva S, Crombie JL, et al. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated chronic lympho- cytic leukemia (CLL). Blood. 2019; 134(Suppl 1):S32.
haematologica | 2021; 106(9)
2363